Table 1.
Patient Characteristics (P/V: pembrolizumab/vemurafenib, P/V/C: pembrolizumab/vemurafenib/cobimetinib).
| Patient Characteristic | Overall Group | Cohort 1(P/V) | Cohort 2 (P/V/C) |
|---|---|---|---|
| ( n=9) | (n=4) | (n=5) | |
| Median age(years) | 58 | 65 | 57 |
| Male sex | 6 | 4 | 2 |
| Female sex | 3 | 0 | 3 |
| White race | 9 | 4 | 5 |
| ECOG | |||
| 0 | 7 | 2 | 5 |
| 1 | 2 | 2 | 0 |
| Disease stage | |||
| Stage IIIC | 1 | 1 | 0 |
| Stage IV | 8 | 3 | 5 |
| Stage, distant metastases | |||
| M1a | 2 | 0 | 2 |
| M1b | 1 | 1 | 0 |
| M1c | 5 | 2 | 3 |
| M1d | 0 | 0 | 0 |
| Sum of target lesions | |||
| <60 mm | 3 | 1 | 2 |
| >60 mm | 6 | 3 | 3 |
| BRAF V600E/K | 9 | 4 | 5 |
| Median LDH | 214 | 193 | 214 |
| Prior adjuvant therapy | 2 | 1 | 1 |